FindMyKOL

Stefanie Ueda, MD

Basic profile

University of California, San Francisco

ORCIDOn fileNPIOn fileSign in to see identifiers
RegionSan Francisco, CA · WestSpecialtyGynecologic OncologyFocusOncology
Last active 2024FindMyKOL typeFindMyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Stefanie Ueda is an Oncology physician affiliated with University of California, San Francisco. OpenAlex indexes 118 publications with 4,980 citations (h-index 24).

Overview

Scholarship

indexed output and impact (OpenAlex)
118publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

4,980citations

Citations across these publications.

24h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
2companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Ethicon US, LLC
    Program year20241 payment
    $56
  • GlaxoSmithKline, LLC.
    Program year20211 payment
    $111

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    45.3%
    Serotonin-3 Receptor Antagonist34.9%
    Ondansetron Hcl100%
    Part D≥14 patients
    Dopamine-2 Receptor Antagonist10.4%
    Metoclopramide Hcl100%
    Part D<11 patients
  • Cancer & immunology

    23.6%
    Kinase inhibitor12.3%
    Lenvima100%
    Part D<11 patients
    Poly(ADP-Ribose) Polymerase Inhibitor11.3%
    Lynparza100%
    Part D<11 patients
  • Sensory organs

    18.9%
    Corticosteroid18.9%
    Dexamethasone100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”